Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine: Useful or not?

NuklearMedizin

Volumn 45, Issue 5, 2006, Pages 213-218

  Dunkelmann, Simone ^a   Kunstner H ^a   Nabavi, E ^a   Eberlein, U ^a   Groth, P ^a   Schumichen C ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Dosimetry; Groves' disease; Lithium; Radioiodine therapy

Indexed keywords

LITHIUM CARBONATE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG UPTAKE; FEMALE; FOLLOW UP; GRAVES DISEASE; HALF LIFE TIME; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; RADIATION DOSE; THYROID FUNCTION;

EID: 33750460569     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625222     Document Type: Article

References (26)

1. 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002; 87: 1073-7.
2. Bal CS, Kumur A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid 2002; 12: 399-505.
3. Bockisch A, Jamitzky T, Derwanz R et al. Optimized dose planning of radioiodine therapy of benign thyroid diseases. J Nuc Med 1993; 34: 1632-8.
4. Bogazzi F, Bartalena L, Campomori A et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. Endocrinol Metab 1999; 84: 499-503.
5. Bogazzi F, Bartalena L, Campomori A et al. Treatment with lithium prevents serum thyroid hormone increase after withdrawal and radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab 2002; 87: 4490-5.
6. Brunn J, Block U, Ruf G et al. Volumetric analysis of thyroid lobes by real-time ultrasound. Dtsch Med Wochenschr 1981; 106: 1338-40.
7. Cartagi B, Leprat F, Guyot M et al. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol 1999; 141: 117-21.
8. Dunkelmann S, Neumann V, Staub U et al. Results of a risk adapted and functional radioiodine therapy in Graves' disease. Nuklearmedizin 2005, 44: 238-42.
9. Groth P, Dunkelmann S, Staub U et al. Stunning der Schilddrüse - ein Früheffekt der Iod-131-Therapie? Nuklearmedizin 2005, 44; A103.
10. Kobe C, Weber I, Sudbrock F, et al. Dosisabhängigkeit des Radioiodtherapieerfolges beim M. Basedow. Nuklearmedizin 2006; 45; A70.
11. Körber C, Schneider P, Körber-Hafher N et al. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in patients with Graves' disease and toxic nodular goitre? Eur J Nucl Med 2001; 28: 1360-4.
12. Larsen PR. Thyroidal triiodthyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status and iodine content. J Clin Endocrinol Metab 1975; 41: 1098-104.
13. Marinelli LD, Quinby EH, Hine GJ. Dosage determination with radioactive isotopes. Practical considerations in therapy and protection. Am J Roentgenol 1948; 59: 260-81.
14. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med 2002; 29: 486-91.
15. th Annual Meeting of the Endocrine Society, San Francisco, 2002; June 19-22; p77.
16. Nüchel C, Boddenberg B, Schicha H. Die Bedeutung des Radioiodtestes für die Berechnung der Therapieaktivität bei gutartigen Schilddrüsenerkrankungen. Nuklearmedizin 1993; 32: 91-8.
17. 131I activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25: 186-93.
18. Rink T, Bormuth FJ, Braun S et al. Concept and validation of a simple model of the intrathyroidal iodine kinetics. Nuklearmedizin 2004; 43: 21-5.
19. Robbins J. Perturbation of iodine metabolism by lithium. Math Biosci 1984; 72: 337-47.
20. Robertson I, Boddy K, Hooper MJ et al. Total thyroidal content of iodine in thyrotoxic patients measured by in vivo neutron activation analysis. Clin Endocrinol 1976; 5: 151-7.
21. Schneider P, Körber C, Körber-Hafner N et al. Verbessert die individuelle Bestimmung der effektiven Halbwertszeit die Ergebnisse der Radioiodtherapie des Morbus Basedow? Nuklearmedizin 2002; 41: 240-4.
22. Schümichen C, Kettmann KB. Kombinierte Radioiod und Lithiumbehandlung der Hyperthyreose. In: Scriba PC, Rudorff KH, Weinheimer B (eds). Schilddrüse 1981. Stuttgart: Thieme 1982; 55-66.
23. Temple R, Berman M, Robbins J et al. The use of lithium in the treatment of thyrotoxicosis. J Clin Invest 1972; 51: 2746-56.
24. Turner JG, Brownlie BE, Rogers TGH. Lithium as an adjunct effect to radioiodine therapy for thyrotoxicosis. Lancet 1976; 1: 614-5.
25. Urbannek V, Schmidt M, Moka D et al. Influence of iodine application during radioiodine therapy in case of impending therapy failure. Nuklearmedizin 2000; 39: 108-12.
26. 131I uptake of the thyroid gland - a model calculation Nuklearmedizin 1996, 35: 251-63.